Robert Faulkner Overview
- Firm
- Redmile Group
- Primary Position
-
Managing Directo...
- Primary Industry
-
Healthcare
- Active Board Seats
-
4
- Med. Deal Size
-
- Med. Valuation
-
Robert Faulkner General Information
Biography
Mr. Robert Faulkner serves as Managing Director at Redmile Group. He serves as Chairman at Science 37. He has been an equity analyst in the medical device industry since 1994. His coverage areas have included, among others, cardiology, orthopedics, urology, vision care, aesthetic surgery, and diabetes. He serves as a Board member at Sphere Fluidics and Call9. He has held positions with Thomas Wiesel Partners, Prudential Financial, and J.P. Morgan Chase & Co. He began his career on Wall Street at S.G. Warburg & Co. (now UBS) where he covered biotechnology and medical device stocks for three years. Before moving to sell-side research, he spent two years with The Wilkerson Group (now IBM), a consulting firm specializing in the assessment of the value of healthcare technologies, and two years at Tuck School of Business at Dartmouth College and graduated from Harvard College. He serves as a board member for Genalyte.
Contact Information
Address
- One Letterman Drive, Building D, Suite D3-300
- The Presidio of San Francisco
- San Francisco, CA 94129
- United States
Robert Faulkner Positions (1)
| Firm name | Firm type | Title | Location | Industry | Since |
|---|---|---|---|---|---|
| Redmile Group | Investor | Managing Director | San Francisco, CA | Hedge Fund |
Robert Faulkner Board Seats (5)
| Company | Industry | Ownership Status | Financing Status | Location | Since |
|---|---|---|---|---|---|
| Augmedix | Enterprise Systems (Healthcare) | Acquired/Merged (Operating Subsidiary) | Formerly VC-backed | San Francisco, CA | |
| Call9 | Other Healthcare Services | Out of Business | Formerly VC-backed | Brooklyn, NY | |
| Genalyte | Laboratory Services (Healthcare) | Privately Held (backing) | Venture Capital-Backed | San Diego, CA | |
| Saluda Medical | Therapeutic Devices | Privately Held (backing) | Venture Capital-Backed | Artarmon, Australia | |
| Sphere Fluidics | Discovery Tools (Healthcare) | Privately Held (backing) | Venture Capital-Backed | Cambridge, United Kingdom |
Robert Faulkner Lead Partner on Deals (12)
| Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
|---|---|---|---|---|---|---|
| Saluda Medical | 06-Apr-2023 | Later Stage VC (Series E) | Completed | Therapeutic Devices | Artarmon, Australia | |
| Genalyte | 06-Mar-2023 | Completed | Laboratory Services (Healthcare) | San Diego, CA | ||
| Saluda Medical | 02-Mar-2022 | Completed | Therapeutic Devices | Artarmon, Australia | ||
| Sphere Fluidics | 28-Oct-2021 | Completed | Discovery Tools (Healthcare) | Cambridge, United Kingdom | ||
| Science 37 | 07-Oct-2021 | Completed | Other Healthcare Services | Culver City, CA | ||
| Genalyte | 11-Jan-2021 | Completed | Laboratory Services (Healthcare) | San Diego, CA | ||
| CorVent | 11-May-2020 | Completed | Monitoring Equipment | Fargo, ND | ||
| Saluda Medical | 27-Jun-2019 | Completed | Therapeutic Devices | Artarmon, Australia | ||
| Xeris Biopharma Holdings | 13-Feb-2018 | Later Stage VC (Series C) | Completed | Drug Discovery | Chicago, IL | |
| Call9 | 14-Sep-2017 | Early Stage VC (Series B) | Completed | Other Healthcare Services | Brooklyn, NY |
Robert Faulkner Network (223)
Board Members (95)
| Name | Company | Representing | Location | From |
|---|---|---|---|---|
| Vijit Sabnis Ph.D | Genalyte | Khosla Ventures | San Diego, CA | |
| Kenneth Hitchner III | Sphere Fluidics | Self | Cambridge, United Kingdom | |
| Sphere Fluidics | Self | Cambridge, United Kingdom | ||
| Augmedix | DCM Ventures | San Francisco, CA | ||
| Call9 | Self | Brooklyn, NY |
Portfolio Executives (125)
| Name | Company | Role | Deal date | Location |
|---|---|---|---|---|
| Tim Benner | Saluda Medical | Chief Commercial Officer | 06-Apr-2023 | Artarmon, Australia |
| Daniel Papallo | Saluda Medical | VP of Finance & Corporate Development | 06-Apr-2023 | Artarmon, Australia |
| Saluda Medical | Chief Financial Officer | 06-Apr-2023 | Artarmon, Australia | |
| Saluda Medical | Chief Technology Officer | 06-Apr-2023 | Artarmon, Australia | |
| Saluda Medical | Chief Financial Officer | 06-Apr-2023 | Artarmon, Australia |
Fund Team Members (3)
| Name | Investor | Fund | Fund Location |
|---|---|---|---|
| Jeremy Green | Redmile Group | Redmile Biopharma Investments I | San Francisco, CA |
| Amrit Nagpal | Redmile Group | Redmile Biopharma Investments I | San Francisco, CA |
| Redmile Group | San Francisco, CA | ||
| Redmile Group | San Francisco, CA | ||
| Redmile Group | San Francisco, CA |
Robert Faulkner Affiliated Funds (3)
| Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
|---|---|---|---|---|---|---|---|---|
| Redmile Biopharma Investments I | Redmile Group | Venture - General | Closed | 2018 | ||||
| Redmile Biopharma Investments II | Redmile Group | Venture - General | Closed | 2020 | ||||
| Redmile Private Investments I | Redmile Group | Buyout | Closed | 2017 |
Robert Faulkner FAQs
-
Who is Robert Faulkner?
Mr. Robert Faulkner serves as Managing Director at Redmile Group.
-
How much does Robert Faulkner typically invest?
Robert Faulkner's median deal size is .
-
What is Robert Faulkner’s main position?
Robert Faulkner’s primary position is Managing Director.
-
What are the contact details for Robert Faulkner?
Robert Faulkner’s email address is rf and his phone number is +1 (917) .
-
How many active board seats does Robert Faulkner hold?
Robert Faulkner holds 5 board seats including Augmedix, Call9, Genalyte, Saluda Medical, and Sphere Fluidics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
